Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
15588125
Knihovny.cz E-zdroje
- MeSH
- antagonisté endotelinového receptoru * MeSH
- aplikace orální MeSH
- bosentan MeSH
- chlorid sodný aplikace a dávkování MeSH
- geneticky modifikovaná zvířata MeSH
- hypertenze komplikace patofyziologie MeSH
- krevní tlak * MeSH
- krysa rodu Rattus MeSH
- míra přežití MeSH
- multiorgánové selhání etiologie patofyziologie MeSH
- potkani Sprague-Dawley MeSH
- receptory endotelinů metabolismus MeSH
- renin-angiotensin systém účinky léků MeSH
- renin genetika metabolismus MeSH
- stupeň závažnosti nemoci MeSH
- sulfonamidy aplikace a dávkování MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antagonisté endotelinového receptoru * MeSH
- bosentan MeSH
- chlorid sodný MeSH
- receptory endotelinů MeSH
- Ren2 protein, mouse MeSH Prohlížeč
- renin MeSH
- sulfonamidy MeSH
The present study was performed to evaluate the role of an interaction between the endothelin (ET) and the renin-angiotensin systems (RAS) in the development and maintenance of hypertension and in hypertension-associated end-organ damage in heterozygous male and female transgenic rats harboring the mouse Ren-2 renin gene (TGR). Twenty-eight days old heterozygous TGR and age-matched transgene-negative normotensive Hannover Sprague-Dawley rats (HanSD) were randomly assigned to groups with normal-salt (NS) or high-salt (HS) intake. Nonselective ET(A)/ET(B) receptor blockade was achieved with bosentan (100 mg.kg(-1).day(-1)). All male and female HanSD as well as heterozygous TGR on NS exhibited 100 % survival rate until 180 days of age (end of experiment). HS diet in heterozygous TGR induced a transition from benign to malignant phase hypertension. The survival rates in male and in female heterozygous TGR on the HS diet were 46 % and 80 %, respectively, and were significantly improved by administration of bosentan to 76 % and 97 %, respectively. Treatment with bosentan did not influence either the course of hypertension (measured by plethysmography in conscious animals) or the final levels of blood pressure (measured by a direct method in anesthetized rats) in any of the experimental groups of HanSD or TGR. Administration of bosentan in heterozygous TGR fed the HS diet markedly reduced proteinuria, glomerulosclerosis and attenuated the development of cardiac hypertrophy compared with untreated TGR. Our data show that the ET receptor blockade markedly improves the survival rate and ameliorates end-organ damage in heterozygous TGR exposed to HS diet. These findings indicate that the interaction between the RAS and ET systems plays an important role in the development of hypertension-associated end-organ damage in TGR exposed to salt-loading.
Hypertension after the Menopause: What Can We Learn from Experimental Studies?